SLC38A2 and lung carcinoma: Notably, higher SLC38A2 expression is associated with poor survival in lung cancer patients whose tumors exhibited SMARCA4 deletion, but not in patients whose tumors did not harbor SMARCA4 alterations (Fig. 5b).